Tb Screening Updates: New Diagnostics and Why Testing Protocol Is Changing
By Sophia Al-Mansoor
The clinical landscape no longer relies exclusively on hundred-year-old PPD protocols. Blood-based interferon-gamma release assays (IGRAs) and newer molecular tools are replacing multi-visit skin evaluations. Research teams at institutions like UC Davis are advancing rapid volatile organic compound detection and targeted breath-based platforms to distinguish active disease without multi-day delays.
| Diagnostic Platform | Biological Target Measured | Turnaround Time | Clinical Strengths & Tradeoffs |
|---|---|---|---|
| Mantoux PPD Skin Test | T-cell mediated dermal induration | 48, 72 hours (Requires two visits) | Low material cost; vulnerable to BCG cross-reactivity and subjective palpation error. |
| IGRA Blood Tests (QuantiFERON / T-SPOT) | Interferon-gamma release from sensitized T-cells | 24, 48 hours (Single blood draw) | Unaffected by prior BCG vaccination; higher laboratory fees; requires strict specimen handling. |
| UC Davis Rapid Biosensing Prototypes | Specific volatile organic compounds (VOCs) | Under 60 minutes | Non-invasive; directly reflects active disease state; currently transitioning through clinical trials. |
Sophia analyzes international trade, startup ecosystems, retail transformation, and supply chain logistics for modern digital publications.
Tags:
what do positive tb test look like
